Meritage Portfolio Management Innoviva, Inc. Transaction History

Meritage Portfolio Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$11.39 - $13.72 $105,995 - $127,678	9,306 Added 42.38%	31,266 $398,000
Q1 2023 Apr 25, 2023	BUY	$10.73 - $13.6 $9,882 - $12,525	921 Added 4.38%	21,960 $247,000
Q4 2022 Feb 01, 2023	BUY	$11.8 - $13.78 $6,029 - $7,041	511 Added 2.49%	21,039 $279,000
Q3 2022 Oct 25, 2022	BUY	$11.61 - $15.22 $19,319 - $25,326	1,664 Added 8.82%	20,528 $238,000
Q2 2022 Jul 25, 2022	BUY	$14.32 - $19.88 $270,132 - $375,016	18,864 New	18,864 $278,000
Q1 2019 Apr 25, 2019	SELL	$13.69 - $20.06 $3.94 Million - $5.78 Million	-287,897 Closed	0 $0
Q4 2018 Jan 25, 2019	SELL	$13.96 - $18.26 $93,322 - $122,068	-6,685 Reduced 2.27%	287,897 $5.02 Million
Q3 2018 Oct 30, 2018	SELL	$13.63 - $15.7 $29,249 - $33,692	-2,146 Reduced 0.72%	294,582 $4.49 Million
Q2 2018 Jul 25, 2018	BUY	$13.44 - $17.59 $73,342 - $95,988	5,457 Added 1.87%	296,728 $4.1 Million
Q1 2018 Apr 26, 2018	BUY	$13.8 - $16.99 $4.02 Million - $4.95 Million	291,271 New	291,271 $4.86 Million

228

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.2B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

Stay updated on Meritage Portfolio Management with notifications on news.